GA_P advises in Oryzon Genomics new capital increase
Gómez-Acebo & Pombo has advised Oryzon Genomics, a biotechnology company whose shares are listed on the Continuous Market, in its capital increase through the issuance of more than 12.7 million new ordinary shares at a price of 2.35 euros per share, increasing the company’s capital by 30 million euros.
The transaction was carried out through an accelerated bookbuild offering.
Oryzon will use the funds to strengthen its financial structure, prepare its IPO on Nasdaq and expand its clinical programs in neuroscience and oncology.
The firm´s team was formed by Augusto Piñel, Jacobo Palanca and Irene Carreño Uría, partner and associates of the Corporate and Capital Markets team.
